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ABSTRACT
Background: Non-adherence impacts negatively
on patient health outcomes and has associated
economic costs. Understanding drivers of
treatment adherence in immune-mediated
inflammatory diseases is key for the development
of effective strategies to tackle non-adherence.
Objective: To identify factors associated with
treatment non-adherence across diseases in
three clinical areas: rheumatology,
gastroenterology, and dermatology.
Design: Systematic review.
Data Sources: Articles published in PubMed,
Science Direct, PsychINFO and the Cochrane
Library from January 1, 1980 to February 14,
2014.
Study Selection: Studies were eligible if they
included patients with a diagnosis of
rheumatoid arthritis, ankylosing spondylitis,
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psoriatic arthritis, inflammatory bowel disease,
or psoriasis and included statistics to examine
associations of factors with non-adherence.
Data Extraction: Data were extracted by the
first reviewer using a standardized 23-item form
and verified by a second/third reviewer. Quality
assessment was carried out for each study using
a 16-item quality checklist.
Results: 73 studies were identified for inclusion
in the review. Demographic or clinical factors
were not consistently associated with
non-adherence. Limited evidence was found
for an association between non-adherence and
treatment factors such as dosing frequency.
Consistent associations with adherence were
found for psychosocial factors, with the
strongest evidence for the impact of the
healthcare professional–patient relationship,
perceptions of treatment concerns and
depression, lower treatment self-efficacy and
necessity beliefs, and practical barriers to
treatment.
Conclusions: While examined in only a
minority of studies, the strongest evidence
found for non-adherence were psychosocial
factors. Interventions designed to address
these factors may be most effective in tackling
treatment non-adherence.
Keywords: Inflammatory bowel disease;
Patient adherence; Psoriasis; Psoriatic arthritis;
Rheumatology
INTRODUCTION
Immune-mediated inflammatory diseases (IMIDs)
refer to a group of chronic conditions that share
common inflammatory pathways [1]. IMIDs
include conditions such as inflammatory bowel
disease (IBD), psoriasis (PS) and rheumatologic
conditions (RC) including rheumatoid arthritis
(RA), ankylosing spondylitis (AS), and psoriatic
arthritis (PsA). IMIDs affect approximately 5–7%
of Western populations and can have a
detrimental effect on quality of life and health
outcomes [1]. In line with other chronic
conditions, sub-optimal adherence to treatment
has been reported in a number of systematic
reviews. Persistence or adherence rates to
treatments for IMIDs were found to range from
30% to 80% in RA [2], 7% to 72% in IBD [3], and
33% to 78% in PS [4].
Increasing adherence may have a far greater
impact on health outcomes than advances in
medical treatments [5, 6]. There are also associated
economic implications such as increased
medication costs, resources used including
hospital admissions, inadequate use of
healthcare professionals’ time, and increased
sickness-related work absence [7]. Thus,
understanding the key drivers of non-adherence
to the types of treatments used across IMIDs is an
important area of investigation and key for the
development of effective strategies to tackle
non-adherence. Further, the identification of
generic tools and/or interventions common to
IMIDs would enable the identification of key areas
likely to be important for adherence and assist the
clinician to identify and address patient concerns
in their consultations.
Although there are existing systematic
reviews looking at factors associated with
non-adherence in the individual clinical areas
(i.e., RA, IBD, or PS), there is a clear need for a
broad understanding of the determinants of
adherence across IMIDs [2–4, 8–19].
AIMS
To our knowledge, no systematic review to date
has examined factors associated with adherence
across several IMIDs or included multiple
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treatment types. The purpose of the current
review is, therefore, to examine factors
associated with adherence in selected IMIDs
across rheumatology, gastroenterology and
dermatology in a systematic way. This could
enable the identification of associations not
only in each therapeutic area but also those in
common across the therapeutic areas.
Identification of key factors will allow
interventions to focus on areas most likely to
have an impact on non-adherence. If there are
factors that are found to be common across
these IMIDs, this will afford the opportunity to
develop cross-condition tools for the health
care professional (HCP) both to identify areas of
non-adherence risk and for generic
interventions, which may be particularly
useful for rheumatologists who are likely to
treat patients with different manifestations of
their IMIDs.
METHODS
The systematic review followed guidelines
developed by the National Institute for
Clinical Excellence (NICE) and the Centre for
Reviews and Dissemination, University of York
[18, 19].
Literature Search and Selection
A search of the literature was conducted via the
following online databases: PubMed, Science
Direct, PsychINFO and the Cochrane Central
Register of Clinical Trials. A broad search
strategy was developed to capture each disease
within the examined clinical areas (see Fig. 1).
In addition, the reference lists of relevant
articles identified through the database search
and existing systematic reviews were searched
manually to identify further suitable studies.
The search was limited to articles published
from January 1, 1980 to February 14, 2014. The
reason for limiting the search to articles
published after January 1980 was that a
previous systematic review identified that
general research interest in treatment
adherence began around 1980 [3].
The search was conducted individually for
each of the selected IMIDs within the five
clinical areas: RA, AS, PsA and IBD and PS.
Initially, the titles and abstracts of the articles
identified through the search strategies were
screened by a first reviewer for eligibility (SB, AF
or DB). The full text was then obtained for all
shortlisted studies and independently reviewed
by a second reviewer (AB). Disagreements
between the two reviewers were resolved by
discussion and independently assessed by a
third reviewer (EV or JW).
Inclusion/Exclusion Criteria
Studies were eligible for inclusion in the review
if they met all the criteria below:
• Published/in press between January 1, 1980
and February 14, 2014.
• Written in English language.
• Included patients with a diagnosis of RA, AS
or PsA, IBD, or PS.
• Based primarily on adult samples
(C18 years).
• Included statistics to examine associations of
factors with non-adherence.
• Used a specified measure of adherence
(validated or non-validated).
• Included adherence measurement of
injection or infusion, oral, rectal or
transdermal formulation (excluding
parenteral nutrition).
• Contained primary quantitative data.
• All participants were on a disease-specific
treatment.
Adv Ther (2015) 32:983–1028 985
• Full study published in a peer-review journal
(i.e., not a conference abstract).
Studies in other clinical indications were
included as long as specific information on one
of the conditions of interest was explicit within
the results. The decision was taken to exclude
studies examining adherence to topical
treatments alone, as topical treatments are not
used across all three clinical areas and are
typically prescribed in mild cases of PS only.
Quality Appraisal
Quality assessment was carried out for each
study to examine their susceptibility to bias in
terms of rigor, methods and analysis. A 16-item
quality checklist adapted from a previous
systematic review of a similar nature [3] based
on guidance from NICE and Strengthening the
Reporting of Observational studies in
Epidemiology was completed for each study.
Search terms used in all systemac reviews:
adhere$..ab. OR complian$..ab. OR comply..ab. OR concordanc$..ab. OR non-
adheren$..ab. OR non-complian$..ab. OR persistence..ab. OR nonadheren$..ab.
AND
medic$..ab. OR treat$..ab. OR therap$..ab.
Limits: restricted to 1 January 1980 to 14 February 2014
Addional search terms used in the RA, AS & PA review:
AND
Arthrit$..ab. OR spondylis..ab. 
AND
ankylosing..ab. OR psoriac..ab. OR rheumat$..ab. OR RA..ab. 
Addional search terms used in the IBD review:
AND
ibd.,ab. OR (inﬂammatory adj bowel adj disease).,ab. OR UC.,ab. OR (ulcerave adj 
colis).,ab. OR (crohn’s adj disease).,ab. OR crohn$.,ab. 
Addional search terms used in the Psoriasis review:
AND 
psoriasis.,ab. OR psoriac.,ab. 
Fig. 1 Search terms
986 Adv Ther (2015) 32:983–1028
Although studies were not excluded or ranked
according to quality, an overall quality score,
based on the total number of quality criteria
met, was computed for each study. Quality
scores were used as general indicators for each
study and are presented in the overview
tables of included studies. Common quality
limitations are explored in more detail in the
‘‘Results’’ section.
Data Extraction and Synthesis
Studies identified through each individual
search were combined for data synthesis and
extraction. For each eligible study, data were
extracted by the first reviewer using a
standardized form consisting of 23 items,
which included details of measures that
could potentially relate to non-adherence.
Details of the sample, non-adherence
measure and potential associates examined
were extracted and tabulated by the first
reviewer and verified by the second and
third reviewers. There was an 85% initial
agreement in the data extracted and all
discrepancies were resolved through
discussion between the reviewers.
Due to the heterogeneity of the included
studies, it was not possible to perform a
meta-analysis of the findings. Frequencies and
proportions of studies examining similar
variables and any association observed were
calculated to offer a simple indication of the
level of evidence. As such, the evidence was
primarily synthesized in a narrative review and
quantified in terms of the proportions of studies
finding an association. As no two studies
controlled for the same variables and the
quality of these studies varied considerably,
preference was not given to findings from
adjusted analyses. Where associations were
found for a factor and these were all in the
same direction, the association was considered
to be consistent.
Compliance with Ethical Guidelines
This article is based on previously conducted
studies and does not involve any new studies of




A total of 73 studies met the inclusion criteria
and were included in the combined review:
RC = 26 (RA = 23; AS = 1; PsA = 11); IBD = 36;
PS = 11 [20–92]. Details regarding the study
selection and exclusion process followed are
presented in Figs. 2, 3 and 4. A summary of the
characteristics of the studies and the factors
examined in each study are shown in Tables 1, 2
and 3 Studies from the same authors were
checked for overlapping samples, and where
there was overlap in the samples, the studies
examined different possible predictors of
adherence [69, 70].
The sample size of the studies varied
considerably, ranging from 28 to 12,750
participants. The vast majority of studies
(90.4%) were based on samples from Europe
(n = 37, 51%) or North America (n = 30, 41%).
Participants were derived from outpatient
clinics in the majority of samples. In RC, this
was 76.9% (n = 20), in IBD (n = 25, 69.4%) and
in PS (n = 8, 72.7%). One sample in RC [23] was
recruited in a clinical trial and two samples in
IBD [69, 79] were convenience samples
recruited online through social media or IBD
forums. The remaining samples were
established cohorts drawn from medical or
pharmacy databases.
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The proportion of longitudinal studies
(including retrospective cohorts) was 57.8%
(n = 15) in RC, 36.1% (n = 13) in IBD, and
72.7% (n = 8) in PS. While a substantial
proportion of studies had a longitudinal
design, factors were most often examined as
concurrent associates of adherence and not as
prospective predictors. Thus, in the current
review all factors are considered as potential
associates of adherence.
A large proportion of studies (57.5%) used
self-report measures to assess adherence. In RC,
the medication event monitoring system
(MEMS) was used to measure non-adherence
in three studies [28, 34, 44], others used pill
counts and pharmacy refill data [22, 23, 27] or
plasma analysis [21]. Five studies had a measure
of medication persistence (i.e., continuation
with a medication) as the adherence outcome,
obtained via HCP report [36, 38] or patient
records/case notes [25, 26, 45]. In IBD, three
studies combined self-report measurement with
a biochemical measure [39, 53, 59]. One study
assessed adherence using a biological measure
only [58] and another via infusion appointment
attendance [12]. The remaining five studies
Arcles subject to abstract review 
n= 201 
Excluded based on abstract 
n=148 
Full arcles retrieved for in-depth 
review 
n=53 
Excluded  n=27 
Included studies 
n=26 
Arcles idenﬁed:  
Electronic search: n= 1199 
Hand searches:  n=4   Total: n=1203 
Duplicates removed and arcles 
excluded based on tle 
n=1002 
Fig. 2 Flowchart of included studies: rheumatologic
conditions, reasons for exclusion of ﬁnal 27 studies
included: did not statistically examine factors associated
with adherence (n = 8, original search) (n = 7, update
search), full study data not reported (n = 1, original
search), did not deﬁne measure of adherence (n = 9,
original search) (n = 1, update search), intervention
examined in relation to adherence (n = 1, original search)
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used a proxy measure of adherence via
prescription refill data [41, 49–51, 76]. In PS,
two studies assessed adherence using a proxy
measure from prescription refill data [83, 85]. A
further three studies had a measure of
medication persistence as the adherence
outcome obtained from patient medical
records [86–88]. Two studies assessed
adherence with respect to unused treatment
medication ascertained via pill counts weight
[89, 92].
Quality of Included Studies
The proportion of quality criteria met by each
study varied widely across the three clinical
areas, ranging between 31% and 87.5% in RC,
25% and 93.8% in IBD, and 25% and 58.3% in
PS. The included studies in RC typically met the
highest proportion of quality criteria, whereas
those in PS met the least. Quality criteria most
commonly not met related to details of the
study required to enable an assessment of bias.
Full arcles retrieved for in-depth 
review 
n=56 
Excluded n= 20 
Included studies 
Total: n=36 
Arcles subject to abstract 
review 
n=175 
Excluded based on abstract 
n=119 
Arcles idenﬁed:  
Electronic search: n=1325 
Duplicates removed and arcles 
excluded based on tle 
n=1150 
Fig. 3 Flowchart of included studies: inﬂammatory bowel
disease, reasons for exclusion of ﬁnal 20 studies included:
did not statistically examine factors associated with
adherence (n = 10, original search) (n = 1, update search),
did not deﬁne measure of adherence (n = 5, original
search), intervention examined in relation to adherence
(n = 2, original search), adherence examined in sample of
pregnant women only (n = 2, original search)
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A number of studies did not report details of
eligibility criteria (n = 15, 20.5%) or the
number of participants not consenting to
participate in the study (n = 42, 57.5%), so it
was not possible to make an assessment of
biases due to participant selection. Similarly,
failure to report how missing data were treated
(n = 65, 89%) and control for confounders
(n = 35; 52%) was common preventing an
assessment of the strength of the associations
found. The majority of studies did not report
power calculations (n = 56, 77%) to estimate
their sample sizes and as such it was difficult to
assess whether studies were adequately powered
to detect associations. However, several studies
had very small sample sizes that were unlikely
to result in adequate power for the statistics
applied.






Arcles subject to abstract: 
 n=92 
Excluded based on abstract 
n=62 
Arcles idenﬁed:  
Electronic search: n=527 
Duplicates removed and arcles 
excluded based on tle 
n=435 
Fig. 4 Flowchart of included studies: psoriasis reasons for
exclusion of ﬁnal 19 studies included: did not statistically
examine factors associated with adherence (n = 7, original
search) (n = 6, update search), examined topical
treatments only (n = 5, original search), intervention
examined in relation to adherence (n = 1, original search)
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Overview of Findings
Adherence rates varied considerably in all
clinical areas and ranged between 7% and 75%
in RC, 4% and 72% in IBD, and 8% and 87% in
PS. Evidence of an association of rates according
to the adherence measure type (e.g., self-report,
MEMs, biochemical, medication possession
ratio) was not found. Factors assessed in
relation to non-adherence were collated into
four key categories: demographic; clinical;
treatment; and psychosocial. All the factors
explored across two or more chronic
conditions, or in one condition and in a
minimum of two studies with consistent
results are presented in Table 4. The
table summarizes the frequency of studies
examining these factors and proportion of
studies to find a statistically significant
association.
Demographic Factors
Age and gender were the most commonly
examined factors (79.5% and 80.8%) in
relation to adherence across conditions. The
majority of studies to examine them (n = 38,
65.5% and n = 44, 74.6%, respectively) found
no association with adherence and, where these
were found, the findings were not consistent.
The exception was for IBD where older age was
found to be associated with greater likelihood of
adherence in all studies to find an association
(n = 11). However, an association was found in
only a minority of the IBD studies; the majority
(i.e., 18 out of 29) found age not to be associated
with adherence. Marital status, education level,
socioeconomic status, employment status,
income, insurance type, geographical location
and ethnicity were not consistently associated
with non-adherence across diseases.
Clinical Factors
Clinical factors were the second most
commonly examined (see Table 4). Disease
duration and disease activity were the two
clinical factors examined most frequently
(n = 37 and n = 28). However, only a small
proportion of these studies (21.6% and 25%)
found an association with adherence, and
where associations were found, the
relationship was not found to be consistent. In
some cases, the relationship between disease
duration and activity was positively associated
with adherence, while in others there was a
negative association. Disease severity and lesion
location, although only examined in a minority
of studies (n = 10 and n = 2), reported the most
consistent associations. In the PS studies,
disease severity was the most commonly
examined clinical factor in relation to
adherence (45.5%). An association with
adherence was found in three of these studies
(60%), in which patients with lower disease
severity were more likely to be non-adherent to
their PS treatment than those with greater
disease severity [84, 90, 92]. Only two of the
five IBD studies (40%) to examine this reported
an association between disease severity and
adherence and the direction of this association
conflicted. None of the included RC studies
examined disease severity.
Location of psoriatic lesions was examined
in two of the PS studies (18%).
Non-adherence was found to be more likely
among patients with facial lesions compared
to those with lesions restricted to the rest of
the body or with increasing number of lesion
sites [92] and among those with greater body
surface area of lesions [72]. Further details
about these studies are available in the
Tables 1, 2, 3 and 4.
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Treatment Factors
Medication type, dosing frequency, and
previous treatment showed the most frequent
association with adherence in the treatment
category. Medication type was the most
commonly explored treatment factor, which
was assessed in 40 studies (54.8%) with an
association to non-adherence reported in over
half of these studies (52.5%).
In RC, non-steroidal anti-inflammatory drugs
(NSAIDs) were found to be associated with lower
adherence levels than disease-modifying
medications [conventional synthetic
disease-modifying anti-rheumatic drugs
(csDMARDs)] in one study [28]. Another study
found an association only for patients on steroids
with these more likely to be adherent than those
patients on NSAIDs or csDMARDs [40], although
no association with corticosteroid use was
observed in the other study examining this [36].
Among anti-tumor necrosis factor (TNF)
treatments, significantly higher discontinuation
rates and lower adherence levels were found for
the biologic infliximab compared to the biologic
etanercept and adalimumab [31, 38].
In IBD, greater adherence was associated
with patients receiving anti-TNF (versus
Prednisolone, Budesonide, exclusive enteral
nutrition and 5-aminosalicylic acid (5-ASAs)
[58], immunomodulator (versus 5-ASA) [46,
54, 56], and steroid treatments compared to
those who prescribed other medications
(including 5-ASAs, immunosuppressants and
antibiotics) [74]. In another study,
non-adherence was reported to be more
frequent in treatment with 5-ASAs compared
to treatment with thiopurines and biological
therapy [75]. Patients on oral treatment were
more likely to be adherent compared to those
on topical and enema treatments in another
study [53].
Persistence rates were significantly higher for
patients taking non-sulfasalazine 5-ASA
compared to those taking sulfasalazine 5-ASA in
one study [76], whereas in another study
persistence was higher for those prescribed a
multi-matrix system mesalamine 5-ASA
compared to those prescribed balsalazide,
mesalamine delayed release or sulfasalazine
5-ASAs [81]. In PS, six studies looked for
associations according to biological DMARD,
with higher persistence to adalimumab or
etanercept compared to infliximab in one study
[88], higher persistence to etanercept compared
to both adalimumab and infliximab in another
study [87] and higher persistence to ustekinumab
compared with other anti-TNFs found in two
studies [86, 91]. The other two studies found no
difference in levels of adherence between
adalimumab and etanercept [85] or between
alefacept, efalizumab or etanercept [83].
The number of doses taken daily was
explored in seven studies across the diseases,
of which the majority found an association
(71.4%, n = 5). While the dosing frequencies
examined varied between studies, associations
were consistent, in that a greater likelihood of
adherence to treatment was found with less
frequent dosing.
Previous treatment was explored in five
studies, four of which found an association
with adherence (80%). Three of these studies
reported that previous exposure to the same
drug or similar type of treatment increased the
likelihood of non-adherence/early
discontinuation [31, 88, 92]. This may be due
to confounding factors such as lack of efficacy
or acquired resistance to the drug class. The
remaining study, reported that not having used
rectal 5-ASA or immunosuppressive/biologic
agents, was associated with the risk of
non-persistence and non-adherence to 5-ASAs
[81].
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Psychosocial Factors
Thirteen psychosocial factors were examined in
relation to adherence (see Table 4). Psychosocial
factors were most commonly examined in the
studies of IBD, followed by RC and were rarely
examined in studies of PS. Treatment beliefs
(i.e., necessity, concerns and efficacy),
emotional well-being (depression and anxiety),
HCP–patient relationship, treatment
self-efficacy (i.e., confidence in one’s ability to
follow treatment) and practical barriers (e.g.,
frequent traveling, forgetfulness, etc.) were
found to be associated with non-adherence in
at least 50% of the studies to examine these.
Non-adherence was found to be associated with
doubts about treatment necessity in 55.6% of
the studies to examine this [29, 40, 57, 68, 75].
Similarly, concerns about side effects and low
perception of treatment efficacy were found to
be associated with non-adherence in 70% and
50% of studies to examine this, respectively [29,
33, 39, 40, 57, 68, 78, 84]. Four of the ten studies
in RC and IBD to examine depression found a
consistent association with non-adherence,
with greater non-adherence reported amongst
patients with depression or depressive
symptoms. For anxiety, while over a third of
the studies to examine this (n = 3, 37.5%) found
an association with non-adherence, the
direction of association was inconsistent. No
studies assessed depression or anxiety in
patients with PS. Practical barriers (e.g.,
frequent traveling, forgetfulness, etc.) were
explored in six studies, and five of these found
non-adherence to be more likely when practical
barriers to taking treatment were perceived to
be present. There was also some evidence that
low levels of trust and satisfaction in the
HCP–patient relationship may increase
treatment non-adherence, with an association
reported in 77.8% of the studies to examine this
[32, 37, 40, 43, 71, 74, 77]. This factor was not
examined in any of the PS studies. Lower
treatment self-efficacy was significantly and
consistently associated with poorer medication
adherence in all three studies of RC [23, 28, 39].
This factor was not examined in any of the IBD
or PS studies.
DISCUSSION
This is the first review to systematically
examine factors associated with
non-adherence to treatment specifically for
patients with selected IMIDs across three
clinical areas. Demographic factors were the
most commonly examined in relation to
non-adherence followed by clinical and
treatment factors. Psychosocial factors were
examined in a minority of studies in RC and
IBD and rarely examined in the PS studies.
However, several consistent associations with
adherence were observed for psychosocial
factors that appear independent of the
therapeutic area assessed.
While examined most commonly, none of
the demographic or clinical factors were found
to be consistently associated with
non-adherence. Despite the general beliefs that
some demographic factors are associated with
non-adherence, this finding is in line with the
other systematic literature reviews, where there
is no consistent relationship between
demographic characteristics and adherence in
patients with chronic conditions [2–4]. Of the
demographic factors, there was some evidence
of an association between older age and
adherence to IBD treatments; however, further
studies are necessary to fully determine this.
With the clinical factors, there was some
evidence that treatment non-adherence may be
more likely among patients with PS with greater
number/body surface area of lesions and among
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those with facial lesions in both studies to
examine them. While the association of greater
non-adherence with increased lesion coverage
may appear counterintuitive, the visibility of
psoriatic lesions to others well-being is put
forward as a main stigmatizing factor from the
patients’ perspective which may have a
significant impact on perceptions of body
image and well-being [93], thus it is possible
that the observed association is mediated by
psychosocial factors such as anxiety or
depression, the effects of which are discussed
below. However, it is important to note the
observed association is based on only two
studies rated to be of medium to low quality.
Some evidence of an association was also
found with the treatment factors including
frequency of dosing and medication type. Due
to wide heterogeneity in the medication types
assessed, and scarce comparison studies among
drug classes and between oral and
injectable medications, it is not possible to
draw conclusions as to which types of
medication are associated with greater
non-adherence. Consistent with some earlier
studies [94, 95], less frequent dosing was
associated with increased adherence, which
may reflect the lower demand on memory and
planning for the patient. However, it was not
possible to assess whether there was a dosing
frequency above which the likelihood of
treatment non-adherence is increased, again
due to wide heterogeneity in dosing
frequencies assessed.
Psychosocial factors were only explored in a
minority of studies. Despite heterogeneity in
measures used, several consistent associations
were observed. In particular, the current review
found evidence that lower perceptions of
treatment necessity [29, 40, 57, 68, 75] and of
treatment efficacy [78, 84], greater treatment
concern [39, 78, 84] and higher HCP–patient
discordance [32, 37, 40, 43, 71] were associated
with greater likelihood of non-adherence.
Similar associations have been observed for
necessity and concern beliefs about
medication and the HCP–patient relationship
in previous reviews of adherence in IBD and RA
specifically [3, 13, 15, 17], as well as in a
systematic review across multiple conditions
[96]. This suggests that addressing treatment
concerns, increasing understanding of
treatment necessity, and enhancing
HCP–patient communication may be
paramount to facilitate treatment adherence,
irrespective of the type of IMID.
Evidence of an association of poorer
emotional well-being, particularly depression,
with non-adherence was found in the current
review. Associations between anxiety and
non-adherence on the other hand were less
consistent, indicating that if an association
exists, this may be weaker. These findings are
consistent with those of a systematic review of
studies of patients across a range of chronic
conditions [97]. Both reviews suggest that
depression but not anxiety may be a risk factor
for treatment non-adherence in IMIDs, as well
as chronic conditions more generally. This
finding is of high importance, as depression is
a potentially modifiable factor if diagnosed and
treated appropriately, thus reducing the
likelihood of poor adherence. It also raises an
important question about the nature of the
process in this effect. For example, depression
might have effects on memory and planning
ability, as well as on beliefs about treatment and
efficacy [97, 98].
Treatment self-efficacy may also be an
important factor for treatment adherence.
Thus, patients with stronger beliefs in their
ability to follow treatment were found to be
more likely to adhere than those with
comparatively weaker self-efficacy beliefs.
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Although, this was only examined in studies of
RC, previous systematic reviews have found
treatment self-efficacy to be closely related to
adherence in a number of different chronic
conditions [96]. However, to enable firm
conclusions to be drawn, further research is
needed to investigate these factors among
patients specifically with PS and IBD.
Evidence of an impact of practical barriers in
treatment adherence was also found in the
current review. The category of practical
barriers is broad and can encompass many
different types. The application of some
topical creams in PS, for example, presents
physical and possibly social barriers to
administering treatment. Frequent traveling,
busy lifestyles or forgetfulness may present
time- and routine-related barriers. While these
barriers on the surface may appear to be
unintentional drivers of non-adherence, recent
research has shown that patient perceptions of
unintentional factors can be predicted by
medication beliefs (intentional non-adherence
factors [99]). This suggests that practical barriers
may reflect in part reduced motivation to take
treatment, and, as such, addressing treatment
beliefs would also be necessary to overcome
them. For this reason, practical barriers are




Limitations to this review and the quality of the
available evidence should be taken into account
when interpreting the findings. For example, it
was not possible to draw conclusions regarding
factors associated across a range of RCs, as the
majority of studies eligible for inclusion were
found for the condition RA. Similarly, it was not
possible to draw conclusions as to whether
factors associated with biologic systemic
treatments were comparable to those of other
classes of treatment, due to the lack of studies to
examine this. Further, the majority of the
assessed studies relied on patient-reported and
thus subjective measures of adherence, which
may not be an accurate reflection of true level of
non-adherence. In addition, psychosocial
factors were only explored in a minority of
studies. As evidence for psychosocial factors was
the most consistent, it is important for further
research to focus on understanding the nature
and strength of the relationship of these factors
with treatment adherence. In particular, there is
a strong need for prospective longitudinal
studies to determine whether the factors
identified in the current review predict
treatment non-adherence or are related in
another way. Similarly, there is also a need for
intervention studies in which these factors are
modified to see whether this results in improved
adherence.
The high level of heterogeneity in both the
measures and analysis approaches applied
across studies limits the conclusions that can
be drawn from the synthesis of the data.
Although the type of measure did not
correlate with the overall level of adherence
found, it was not possible to determine whether
the pattern of associations varied according to
the adherence measure used. There was wide
variation in the quality of the studies, which
may have influenced the pattern of findings.
Studies investigating adherence across a range
of IMID conditions using the same measures
and analysis approach are urgently needed to
enable identification of common and consistent
predictors. Efforts to address such limitations
are currently underway in the ALIGN study; a
multi-country, cross-section AL study to
determine patient specific and General beliefs
towards medication and their treatment
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adherence to selected systemic therapies in
chronic inflammatory diseases (IMID) (UKCRN
ID: 12782). It is anticipated that the results of
this study will build on the findings of this
review and further advance our understanding
of the role of factors particularly those of
patient beliefs about treatment for adherence
to systemic therapies.
Implications for Clinical Practice
Although the heterogeneity of the reviewed
studies restricts our ability to draw firm
conclusions, fairly minimal evidence was found
for an impact of demographic, clinical and
treatment factors on treatment non-adherence,
but more consistent evidence was reported for
psychosocial factors. The findings of the current
review indicate that greater treatment concern,
lower treatment self-efficacy and necessity,
presence of depression or practical barriers, and
a sub-optimal HCP–patient relationship may
have a negative impact on treatment
adherence, and these could be considered
modifiable risk factors. At present, assessing
adherence is not always high priority within
clinical practice, due in part to a combination of
time constraints and lack of awareness regarding
the extent and nature of the problem. Even when
adherence is measured, the rates can be of
limited value without the understanding of
potential risk factors, and most importantly,
interventions to address and modify these
psychosocial factors. Increasing clinician
awareness of the adherence problem, however,
does not always result in changes to patient
beliefs and behavior [100]. Twofold
intervention, that focuses on increasing
clinician awareness about the range of factors,
particularly psychosocial that may impact on
treatment non-adherence as well as tools to help
tackle these issues, are thus likely to be most
effective. For example, the development of tools
to help clinicians elicit and address patient
beliefs in routine consultations is recommended.
CONCLUSIONS
Through a systematic analysis of the evidence
across the clinical areas of RC, IBD and PS, this
review has identified common patterns to both
focus research efforts and to support the
development of tools or interventions in
routine care to help patients follow their
prescribed treatment regimen. To date, the
main focus of research in the areas of RC, IBD
and PS has been on the association of
demographic factors, and clinical or treatment
factors. The findings of the current review,
however, suggest that these factors are not
consistent or key determinants of adherence.
It appears that psychosocial factors are more
consistently associated with adherence. As such,
interventions designed to modify these factors
through addressing treatment beliefs, providing
practical advice on taking treatment, and
improving communication between HCPs and
patients may prove to be the most effective.
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